Amedisys Inc (AMED) Shares Sold by Bank of America Corp DE

Bank of America Corp DE lessened its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 2.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 144,774 shares of the health services provider’s stock after selling 4,069 shares during the period. Bank of America Corp DE’s holdings in Amedisys were worth $12,372,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. BlackRock Inc. increased its holdings in Amedisys by 7.5% during the 2nd quarter. BlackRock Inc. now owns 5,382,005 shares of the health services provider’s stock valued at $459,945,000 after purchasing an additional 377,153 shares during the period. Rothschild Asset Management Inc. increased its holdings in Amedisys by 0.3% during the 2nd quarter. Rothschild Asset Management Inc. now owns 447,262 shares of the health services provider’s stock valued at $38,223,000 after purchasing an additional 1,278 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in Amedisys by 9.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 202,546 shares of the health services provider’s stock valued at $17,310,000 after purchasing an additional 16,677 shares during the period. Acadian Asset Management LLC increased its holdings in Amedisys by 148.0% during the 2nd quarter. Acadian Asset Management LLC now owns 191,162 shares of the health services provider’s stock valued at $16,338,000 after purchasing an additional 114,077 shares during the period. Finally, Sei Investments Co. increased its holdings in Amedisys by 762.0% during the 2nd quarter. Sei Investments Co. now owns 123,582 shares of the health services provider’s stock valued at $10,562,000 after purchasing an additional 109,246 shares during the period. Institutional investors own 93.31% of the company’s stock.

Amedisys stock opened at $109.28 on Friday. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.30. The company has a market cap of $3.98 billion, a price-to-earnings ratio of 51.86, a PEG ratio of 1.89 and a beta of 1.00. Amedisys Inc has a fifty-two week low of $45.60 and a fifty-two week high of $127.38.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Tuesday, July 31st. The health services provider reported $1.00 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.78 by $0.22. The business had revenue of $411.60 million for the quarter, compared to analysts’ expectations of $403.62 million. Amedisys had a return on equity of 20.11% and a net margin of 4.46%. During the same period in the previous year, the firm posted $0.62 EPS. As a group, analysts forecast that Amedisys Inc will post 3.41 earnings per share for the current year.

A number of brokerages recently issued reports on AMED. SunTrust Banks boosted their price target on Amedisys to $130.00 and gave the company a “buy” rating in a report on Thursday. Robert W. Baird boosted their price target on Amedisys from $105.00 to $120.00 and gave the company a “neutral” rating in a report on Thursday. Cantor Fitzgerald boosted their price target on Amedisys from $117.00 to $125.00 and gave the company a “neutral” rating in a report on Thursday. BidaskClub downgraded Amedisys from a “strong-buy” rating to a “buy” rating in a report on Monday, June 18th. Finally, Canaccord Genuity started coverage on Amedisys in a report on Thursday, September 13th. They set a “neutral” rating and a $117.00 price target on the stock. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $95.38.

In other Amedisys news, insider David B. Pearce sold 398 shares of Amedisys stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $121.71, for a total transaction of $48,440.58. Following the sale, the insider now directly owns 11,818 shares of the company’s stock, valued at approximately $1,438,368.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 2.60% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Recommended Story: Return on Equity (ROE)

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply